Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Belén Sierro"'
Autor:
Beatriz Guijarro-Albaladejo, Cristina Marrero-Cepeda, Eduardo Rodríguez-Arbolí, Belén Sierro-Martínez, José Antonio Pérez-Simón, Estefanía García-Guerrero
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a poor prognosis despite the advent of novel therapies. Consequently, a major need exists for new therapeutic options, particularly for patients with relapsed/refractory (R/R)
Externí odkaz:
https://doaj.org/article/81603b03bcff49848b5215199be63ec6
Autor:
Belén Sierro Martínez, Clara Beatriz García-Calderón, Estefanía García-Guerrero, Luzalba Sanoja-Flores, Raquel Muñoz-García, Victoria Ruiz-Maldonado, Javier Delgado-Serrano, Águeda Molinos-Quintana, Beatriz Guijarro-Albaladejo, Inmaculada Carrasco-Brocal, Jose Manuel Lucena, José Raúl García-Lozano, Cristina Blázquez-Goñi, Juan Luis Reguera Ortega, María Francisca Gonzalez-Escribano, Marta Reinoso Segura, Javier Briones Meijide, Perez Simon Josè Antonio, Teresa Caballero-Velázquez
Publikováno v:
HemaSphere, Vol 7, p e913221d (2023)
Externí odkaz:
https://doaj.org/article/8133d432cd7a44caa402911b3f538284
Autor:
Clara Beatriz García-Calderón, Belén Sierro-Martínez, Estefanía García-Guerrero, Luzalba Sanoja-Flores, Raquel Muñoz-García, Victoria Ruiz-Maldonado, María Reyes Jimenez-Leon, Javier Delgado-Serrano, Águeda Molinos-Quintana, Beatriz Guijarro-Albaladejo, Inmaculada Carrasco-Brocal, José-Manuel Lucena, José-Raúl García-Lozano, Cristina Blázquez-Goñi, Juan Luis Reguera-Ortega, María-Francisca González-Escribano, Marta Reinoso-Segura, Javier Briones, José Antonio Pérez-Simón, Teresa Caballero-Velázquez
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
PurposeCAR-T cell therapy has proven to be a disruptive treatment in the hematology field, however, less than 50% of patients maintain long-term response and early predictors of outcome are still inconsistently defined. Here, we aimed to optimize the
Externí odkaz:
https://doaj.org/article/e96a06555ede4b65b1cb1ecb9861c04c
Autor:
Estefanía García-Guerrero, Luis G. Rodríguez-Lobato, Belén Sierro-Martínez, Sophia Danhof, Stephan Bates, Silke Frenz, Larissa Haertle, Ralph Götz, Markus Sauer, Leo Rasche, K. Martin Kortüm, Jose A. Pérez-Simón, Hermann Einsele, Michael Hudecek, Sabrina R. Prommersberger
Publikováno v:
Haematologica, Vol 108, Iss 2 (2022)
B-cell maturation antigen (BCMA) is the lead antigen for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). A challenge is inter- and intra-patient heterogeneity in BCMA expression on MM cells and BCMA downmodulation under thera
Externí odkaz:
https://doaj.org/article/c5afb352d346406386ae305b8e18e44f
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Multiple myeloma (MM) remains an incurable disease regardless of recent advances in the field. Therefore, a substantial unmet need exists to treat patients with relapsed/refractory myeloma. The use of novel agents such as daratumumab, elotuzumab, car
Externí odkaz:
https://doaj.org/article/d466e160c57347088ee26f82511a6ff0
Autor:
Belén Sierro, Clara Beatriz Garcia-Calderon, Luzalba Sanoja-Flores, Victoria Ruiz-Maldonado, Javier Delgado Serrano, Agueda Molinos-Quintana, Juan Luis Reguera, Beatriz Guijarro-Albaladejo, Marta Reinoso-Segura, Estefania Garcia-Guerrero, Jose A. Perez-Simon, Teresa Caballero
Publikováno v:
Blood. 140:7550-7551
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dc68c163f01a06e42d6425780d118f4
https://doi.org/10.1182/blood-2022-163106
https://doi.org/10.1182/blood-2022-163106
Autor:
Estefanía, García-Guerrero, Luis G, Rodríguez-Lobato, Belén, Sierro-Martínez, Sophia, Danhof, Stephan, Bates, Silke, Frenz, Larissa, Haertle, Ralph, Götz, Markus, Sauer, Leo, Rasche, K Martin, Kortüm, Jose A, Pérez-Simón, Hermann, Einsele, Michael, Hudecek, Sabrina R, Prommersberger
Publikováno v:
Haematologica.
B-cell maturation antigen (BCMA) is the lead antigen for CAR T-cell therapy in multiple myeloma (MM). A challenge is inter- and intra-patient heterogeneity in BCMA expression on MM cells and BCMA downmodulation under therapeutic pressure. Accordingly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8cff22f1d3748edc0be8916035a068e4
https://pubmed.ncbi.nlm.nih.gov/36047086
https://pubmed.ncbi.nlm.nih.gov/36047086
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology, Vol 11 (2020)
Multiple myeloma (MM) remains an incurable disease regardless of recent advances in the field. Therefore, a substantial unmet need exists to treat patients with relapsed/refractory myeloma. The use of novel agents such as daratumumab, elotuzumab, car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff2dbd030c4a6d3aa512c8680e218bf
https://www.frontiersin.org/articles/10.3389/fimmu.2020.01128/pdf
https://www.frontiersin.org/articles/10.3389/fimmu.2020.01128/pdf
Autor:
Michael Hudecek, Belén Sierro-Martínez, Markus Sauer, José A. Pérez-Simón, Estefanía García-Guerrero, Sophia Danhof, Ralph Goetz, Hermann Einsele, Sabrina Prommersbe, Luis Gerardo Rodríguez-Lobato
Publikováno v:
Blood. 136:13-14
Background: B cell maturation antigen (BCMA) is a B-lineage antigen that is retained on malignant plasma cells in multiple myeloma (MM), and is under investigation as a target antigen for humoral and cellular immunotherapy. Targeting BCMA with chimer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f7989d52c58cb2e37429720d89943d0
https://doi.org/10.1182/blood-2020-142572
https://doi.org/10.1182/blood-2020-142572